4/A//SEC Filing
Schwartz Jonathan David 4/A
Accession 0001140361-23-008101
CIK 0001281895other
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 7:25 PM ET
Size
11.9 KB
Accession
0001140361-23-008101
Insider Transaction Report
Form 4/AAmended
Schwartz Jonathan David
See Remarks
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-02-14+8,574→ 17,410 total→ Common Stock (8,574 underlying) - Exercise/Conversion
Common Stock
2023-02-14+8,574→ 98,103 total - Award
Stock Option (Right to Buy)
2023-02-14+124,496→ 124,496 totalExercise: $20.04Exp: 2033-02-13→ Common Stock (124,496 underlying) - Award
Restricted Stock Units
2023-02-14+41,541→ 41,541 total→ Common Stock (41,541 underlying)
Footnotes (6)
- [F1]The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023.
- [F2]Represents shares of Common Stock received upon vesting of a restricted stock unit award.
- [F3]This option represents a right to purchase a total of 124,496 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
- [F4]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F5]One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
- [F6]One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
Documents
Issuer
ROCKET PHARMACEUTICALS, INC.
CIK 0001281895
Entity typeother
Related Parties
1- filerCIK 0001726398
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 21, 7:00 PM ET
- Accepted
- Feb 22, 7:25 PM ET
- Size
- 11.9 KB